Blog The Next Wave of Metabolic Health: Navigating Phase-3 GLP-1 Pipelines and the Analytical Challenge 17/03/2026 bodhtree NDSRIs (Nitrosamine Drug Substance–Related Impurities): Regulatory Risk, Analytical Challenges, and Control Strategies 27/02/2026 Admin Rubber Oligomers in Extractables & Leachables (E&L) Studies 17/02/2026 Admin Forced Degradation Studies for GLP-1 Peptide Drugs: Establishing Stability, Impurity Profiles, and Regulatory Confidence 08/01/2026 Admin Immunogenicity Risk Assessment of GLP-1 Peptide Drug Impurities: Regulatory and Analytical Perspectives 29/12/2025 Admin Degradation Pathways and Impurity Formation in GLP-1 therapeutics: Liraglutide, Semaglutide, and Tirzepatide 01/12/2025 Admin Certification of GLP-1 Peptide Drug Impurities 24/11/2025 Admin Importance of Cyclic Peptides and Role of Impurities 15/05/2023 Admin Peptide Synthesis: Importance of Impurity Profiling in Therapeutic Peptides 07/04/2023 Admin
The Next Wave of Metabolic Health: Navigating Phase-3 GLP-1 Pipelines and the Analytical Challenge 17/03/2026 bodhtree
NDSRIs (Nitrosamine Drug Substance–Related Impurities): Regulatory Risk, Analytical Challenges, and Control Strategies 27/02/2026 Admin
Forced Degradation Studies for GLP-1 Peptide Drugs: Establishing Stability, Impurity Profiles, and Regulatory Confidence 08/01/2026 Admin
Immunogenicity Risk Assessment of GLP-1 Peptide Drug Impurities: Regulatory and Analytical Perspectives 29/12/2025 Admin
Degradation Pathways and Impurity Formation in GLP-1 therapeutics: Liraglutide, Semaglutide, and Tirzepatide 01/12/2025 Admin
